Introduction
Materials and methods
Study subjects
Comprehensive survival analysis
Statistical analysis
Results
Association analysis of clinical parameters and rs7893462 genotypes
Comprehensive survival analysis
Survival analysis of demographic parameters in HBV-related HCC OS
Survival analysis of rs7893462 polymorphisms in HBV-related HCC OS
Genotype | Patients(n = 468) | MST (months) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted Pɠ |
---|---|---|---|---|---|---|
rs7893462 | ||||||
AA | 112 | 95 | 1 | 1 | ||
AG | 212 | 39 | 1.916 (1.339–2.743) | < 0.0001 | 1.806 (1.240–2.630) | 0.002 |
GG | 144 | 81 | 1.059 (0.707–1.585) | 0.781 | 0.895 (0.586–1.368) | 0.61 |
rs7893462 | ||||||
AG | 212 | 39 | 1 | 1 | ||
AA | 112 | 95 | 0.522 (0.365–0.747) | 0.0004 | 0.554 (0.380–0.807) | 0.002 |
GG | 144 | 81 | 0.553 (0.403–0.7577) | 0.0002 | 0.496 (0.352–0.698) | < 0.0001 |
AA + GG | 256 | 93 | 0.540 (0.413–0.705) | < 0.0001 | 0.519 (0.389–0.693) | < 0.0001 |
rs7893462 | ||||||
AA | 112 | 95 | 1 | 1 | ||
AG + GG | 356 | 48 | 1.515 (1.075–2.136) | 0.018 | 1.351 (0.945–1.932) | 0.099 |
rs7893462 | ||||||
GG | 144 | 81 | 1 | 1 | ||
AA + AG | 324 | 45 | 1.471 (1.088–1.988) | 0.012 | 1.652 (1.194–2.286) | 0.002 |
Nomogram of rs7893462 polymorphisms in HBV-related HCC OS
Stratification analysis of rs7893462 polymorphisms in HBV-related HCC OS
Joint effect survival analysis of rs7893462 polymorphisms in HBV-related HCC OS
Groups | Variables | Genotype | Patients(n = 468) | MST(months) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P |
---|---|---|---|---|---|---|---|---|
Radical resectiona | rs7893462 | |||||||
1 | Yes | AG | 106 | 42 | 1 | 1 | ||
2 | No | AG | 100 | 34 | 1.303 (0.906–1.875) | 0.154 | 1.039 (0.695–1.555) | 0.851 |
3 | Yes | AA + GG | 155 | 84 | 0.558 (0.385–0.808) | 0.002 | 0.591 (0.397–0.881) | 0.01 |
4 | No | AA + GG | 98 | 80 | 0.698 (0.472–1.034) | 0.073 | 0.468 (0.300–0.731) | 0.001 |
Tumor size | ||||||||
I | ≤ 5 cm | AG | 77 | 50 | 1 | 1 | ||
II | > 5 cm | AG | 135 | 28 | 1.754 (1.168–2.632) | 0.007 | 1.557 (0.993–2.441) | 0.054 |
III | ≤ 5 cm | AA + GG | 112 | 123 | 0.449 (0.270–0.747) | 0.002 | 0.418 (0.240–0.727) | 0.002 |
IV | > 5 cm | AA + GG | 144 | 61 | 1.125 (0.740–1.711) | 0.581 | 0.879 (0.555–1.393) | 0.584 |
Tumor number | ||||||||
a | Single | AG | 156 | 42 | 1 | 1 | ||
b | Multiple | AG | 56 | 23 | 1.930 (1.321–2.820) | 0.001 | 1.536 (0.901–2.618) | 0.115 |
c | Single | AA + GG | 190 | 95 | 0.608 (0.440–0.841) | 0.003 | 0.592 (0.417–0.841) | 0.003 |
d | Multiple | AA + GG | 66 | 75 | 0.750 (0.490–1.149) | 0.187 | 0.610 (0.353–1.056) | 0.077 |
BCLC | ||||||||
A | A | AG | 115 | 74 | 1 | 1 | ||
B | B | AG | 34 | 27 | 2.010 (1.228–3.290) | 0.005 | 1.575 (0.781–3.176) | 0.204 |
C | C | AG | 63 | 17 | 3.500 (2.331–5.254) | < 0.0001 | 3.037 (1.539–5.991) | 0.001 |
D | A | AA + GG | 162 | 101 | 0.634 (0.424–0.946) | 0.026 | 0.647 (0.422–0.992) | 0.046 |
E | B | AA + GG | 40 | 75 | 0.925 (0.524–1.632) | 0.788 | 0.706 (0.342–1.455) | 0.345 |
F | C | AA + GG | 54 | 34 | 1.906 (1.220–2.978) | 0.005 | 1.296 (0.656–2.560) | 0.455 |
Portal vein tumor thrombusb | ||||||||
i | No | AG | 166 | 47 | 1 | 1 | ||
ii | Yes | AG | 45 | 14 | 3.598 (2.428–5.332) | < 0.0001 | 1.432 (0.762–2.692) | 0.365 |
iii | No | AA + GG | 217 | 95 | 0.570 (0.415–0.782) | 0.0005 | 0.543 (0.387–0.761) | 0.0004 |
iv | Yes | AA + GG | 39 | 27 | 1.727 (1.102–2.706) | 0.017 | 0.664 (0.335–1.314) | 0.24 |
Serum AFPc | ||||||||
AA | AFP ≤ 400 (ng/mL) | AG | 108 | 41 | 1 | 1 | ||
BB | AFP > 400 (ng/mL) | AG | 86 | 27 | 1.463 (1.004–2.131) | 0.047 | 1.327 (0.900–1.957) | 0.154 |
CC | AFP ≤ 400 (ng/mL) | AA + GG | 133 | 84 | 0.518 (0.350–0.766) | 0.001 | 0.589 (0.395–0.878) | 0.009 |
DD | AFP > 400 (ng/mL) | AA + GG | 107 | 80 | 0.675 (0.456–0.9996) | 0.0498 | 0.604 (0.405–0.902) | 0.014 |
Groups | Variables | Genotype | Patients(n = 468) | MST(months) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P |
---|---|---|---|---|---|---|---|---|
Radical resectiona | rs7893462 | |||||||
A1 | Yes | GG | 89 | 81 | 1 | 1 | ||
B2 | No | GG | 55 | 93 | 1.047 (0.619–1.773) | 0.863 | 0.599 (0.327–1.094) | 0.095 |
C3 | Yes | AA + AG | 172 | 61 | 1.318 (0.883–1.976) | 0.177 | 1.277 (0.831–1.963) | 0.265 |
D4 | No | AA + AG | 143 | 38 | 1.843 (1.238–2.744) | 0.003 | 1.344 (0.858–2.108) | 0.197 |
Tumor size | ||||||||
11 | ≤ 5 cm | GG | 62 | 123 | 1 | 1 | ||
22 | > 5 cm | GG | 82 | 78 | 2.093 (1.199–3.654) | 0.009 | 1.619 (0.870–3.013) | 0.128 |
33 | ≤ 5 cm | AA + AG | 127 | 88 | 1.370 (0.788–2.382) | 0.265 | 1.395 (0.764–2.549) | 0.279 |
44 | > 5 cm | AA + AG | 197 | 36 | 3.032 (1.845–4.984) | < 0.0001 | 2.861 (1.650–4.959) | 0.0002 |
Tumor number | ||||||||
Aa | Single | GG | 109 | 96 | 1 | 1 | ||
Bb | Multiple | GG | 35 | 75 | 1.221 (0.693–2.151) | 0.489 | 0.992 (0.508–1.934) | 0.98 |
Cc | Single | AA + AG | 237 | 52 | 1.350 (0.942–1.937) | 0.102 | 1.487 (1.003–2.205) | 0.048 |
Dd | Multiple | AA + AG | 87 | 28 | 2.253 (1.495–3.395) | 0.0001 | 2.014 (1.164–3.485) | 0.012 |
BCLC | ||||||||
A11 | A | GG | 90 | 101 | 1 | 1 | ||
B22 | B | GG | 22 | 75 | 1.435 (0.698–2.951) | 0.326 | 1.209 (0.512–2.855) | 0.665 |
C33 | C | GG | 32 | 34 | 2.614 (1.461–4.676) | 0.001 | 1.710 (0.765–3.820) | 0.191 |
D44 | A | AA + AG | 187 | 88 | 1.241 (0.802–1.921) | 0.332 | 1.367 (0.846–2.209) | 0.201 |
E55 | B | AA + AG | 52 | 39 | 2.388 (1.430–3.989) | 0.001 | 1.829 (0.901–3.711) | 0.095 |
F66 | C | AA + AG | 85 | 18 | 4.584 (2.935–7.161) | < 0.0001 | 3.691 (1.820–7.484) | 0.0003 |
Portal vein tumor thrombusb | ||||||||
AA1 | No | GG | 123 | 93 | 1 | 1 | ||
BB2 | Yes | GG | 21 | 28 | 2.569 (1.382–4.775) | 0.003 | 1.038 (0.471–2.288) | 0.926 |
CC3 | No | AA + AG | 260 | 71 | 1.336 (0.944–1.891) | 0.102 | 1.474 (1.011–2.149) | 0.043 |
DD4 | Yes | AA + AG | 63 | 14 | 4.886 (3.239–7.371) | < 0.0001 | 2.315 (1.239–4.327) | 0.009 |
Serum AFPc | ||||||||
AAA | AFP ≤ 400 (ng/mL) | GG | 75 | 81 | 1 | 1 | ||
BBB | AFP > 400 (ng/mL) | GG | 57 | 80 | 1.318 (0.756–2.296) | 0.33 | 0.976 (0.555–1.716) | 0.933 |
CCC | AFP ≤ 400 (ng/mL) | AA + AG | 166 | 57 | 1.351 (0.975–2.405) | 0.064 | 1.491 (0.944–2.353) | 0.087 |
DDD | AFP > 400 (ng/mL) | AA + AG | 136 | 38 | 2.080 (1.318–3.284) | 0.002 | 1.783 (1.123–2.832) | 0.014 |
Association analysis of clinical parameters and rs7893462 genotypes
Variables | GG (n = 144) | AA + AG (n = 324) | OR (95%CI) | P | AG (n = 212) | AA + GG (n = 256) | OR (95%CI) | P |
---|---|---|---|---|---|---|---|---|
Age (years) | ||||||||
≤ 60 | 125 | 289 | 1 | 190 | 224 | 1 | ||
> 60 | 19 | 35 | 0.797 (0.439–1.447) | 0.46 | 22 | 32 | 1.234 (0.693–2.195) | 0.475 |
Gender | ||||||||
Male | 126 | 288 | 1 | 194 | 220 | 1 | ||
Female | 18 | 36 | 0.875 (0.479–1.600) | 0.66 | 18 | 36 | 1.764 (0.970–3.207) | 0.063 |
Ethnicity | ||||||||
Han | 94 | 202 | 1 | 133 | 163 | 1 | ||
Minority | 50 | 122 | 1.135 (0.753–1.711) | 0.54 | 79 | 93 | 0.961 (0.659–1.401) | 0.834 |
BMI | ||||||||
≤ 25 | 118 | 251 | 1 | 167 | 202 | 1 | ||
> 25 | 26 | 73 | 1.320 (0.802–2.172) | 0.28 | 45 | 54 | 0.992 (0.635–1.549) | 0.972 |
Smoking status | ||||||||
None | 96 | 212 | 1 | 133 | 175 | 1 | ||
Ever | 48 | 112 | 1.057 (0.698–1.601) | 0.8 | 79 | 81 | 0.779 (0.531–1.143) | 0.202 |
Drinking status | ||||||||
None | 91 | 193 | 1 | 122 | 162 | 1 | ||
Ever | 53 | 131 | 1.165 (0.777–1.747) | 0.46 | 90 | 94 | 0.787 (0.542–1.142) | 0.206 |
Child–Pugha | ||||||||
A | 113 | 268 | 1 | 169 | 212 | 1 | ||
B | 20 | 38 | 0.801 (0.447–1.437) | 0.46 | 28 | 30 | 0.854 (0.491–1.485) | 0.576 |
Cirrhosisb | ||||||||
No | 13 | 43 | 1 | 26 | 30 | 1 | ||
Yes | 131 | 280 | 0.646 (0.336–1.243) | 0.19 | 185 | 226 | 1.059 (0.605–1.853) | 0.842 |
Radical resectionc | ||||||||
Yes | 89 | 172 | 1 | 106 | 155 | 1 | ||
No | 55 | 143 | 1.345 (0.899–2.013) | 0.15 | 100 | 98 | 0.670 (0.462–0.973) | 0.035 |
Pathological diagnosisd | ||||||||
Well differentiated | 11 | 14 | 1 | 11 | 14 | 1 | ||
Moderately differentiated | 106 | 255 | 1.890 (0.831–4.298) | 0.13 | 165 | 196 | 0.933 (0.413–2.111) | 0.868 |
Poorly differentiated | 3 | 8 | 2.095 (0.447–9.814) | 0.35 | 7 | 4 | 0.449 (0.104–1.934) | 0.283 |
Tumor size | ||||||||
≤ 5 cm | 62 | 127 | 1 | 77 | 112 | 1 | ||
> 5 cm | 82 | 197 | 1.173 (0.788–1.747) | 0.43 | 135 | 144 | 0.733 (0.505–1.065) | 0.103 |
Tumor number | ||||||||
Single | 109 | 237 | 1 | 156 | 190 | 1 | ||
Multiple | 35 | 87 | 1.143 (0.727–1.799) | 0.56 | 56 | 66 | 0.968 (0.639–1.464) | 0.876 |
BCLC | ||||||||
A | 90 | 187 | 1 | 115 | 162 | 1 | ||
B | 22 | 52 | 1.138 (0.651–1.988) | 0.65 | 34 | 40 | 0.835 (0.499–1.399) | 0.494 |
C | 32 | 85 | 1.278 (0.793–2.062) | 0.31 | 63 | 54 | 0.608 (0.394–0.940) | 0.025 |
Portal vein tumor thrombuse | ||||||||
No | 123 | 260 | 1 | 166 | 217 | 1 | ||
Yes | 21 | 63 | 1.419 (0.828–2.432) | 0.2 | 45 | 39 | 0.663 (0.413–1.065) | 0.089 |
Serum AFPf | ||||||||
AFP ≤ 400 (ng/mL) | 75 | 166 | 1 | 108 | 133 | 1 | ||
AFP > 400 (ng/mL) | 57 | 136 | 1.078 (0.714–1.628) | 0.72 | 86 | 107 | 1.010 (0.690–1.479) | 0.958 |